Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Net Margin (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Net Margin for 8 consecutive years, with 201.47% as the latest value for Q1 2026.

  • For Q1 2026, Net Margin rose 9528.0% year-over-year to 201.47%; the TTM value through Mar 2026 reached 611.96%, down 20288.0%, while the annual FY2025 figure was 794.04%, 31847.0% down from the prior year.
  • Net Margin hit 201.47% in Q1 2026 for Kymera Therapeutics, up from 3030.7% in the prior quarter.
  • Across five years, Net Margin topped out at 30.01% in Q4 2023 and bottomed at 3030.7% in Q4 2025.
  • Average Net Margin over 5 years is 802.85%, with a median of 432.37% recorded in 2023.
  • Year-over-year, Net Margin soared 18602bps in 2023 and then tumbled -207381bps in 2025.
  • Kymera Therapeutics' Net Margin stood at 216.03% in 2022, then skyrocketed by 86bps to 30.01% in 2023, then crashed by -3089bps to 956.88% in 2024, then crashed by -217bps to 3030.7% in 2025, then surged by 93bps to 201.47% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 201.47%, 3030.7%, and 2973.05% for Q1 2026, Q4 2025, and Q3 2025 respectively.